Looking Into Inhibikase Therapeutics's Return On Capital Employed
December 27, 2022 at 09:46 AM EST
According to data from Benzinga Pro, during Q3, Inhibikase Therapeutics's (NASDAQ:IKT) reported sales totaled $7 thousand. Despite a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.